Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price hoisted by Stifel Nicolaus from $40.00 to $41.00 in a research report report published on Monday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other research analysts have also commented on SNDX. Citigroup lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Barclays boosted their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. Jefferies Financial Group assumed coverage on shares of Syndax Pharmaceuticals in a research report on Friday, June 28th. They set a “buy” rating and a $37.00 price objective on the stock. Bank of America boosted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, HC Wainwright boosted their price objective on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.78.

Syndax Pharmaceuticals Stock Performance

SNDX stock opened at $19.89 on Monday. The firm has a fifty day moving average price of $19.34 and a 200 day moving average price of $20.62. Syndax Pharmaceuticals has a fifty-two week low of $11.22 and a fifty-two week high of $25.34. The firm has a market cap of $1.69 billion, a PE ratio of -6.18 and a beta of 0.91.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. During the same period in the previous year, the business posted ($0.64) earnings per share. The business’s quarterly revenue was up 3499999990.0% compared to the same quarter last year. On average, equities analysts predict that Syndax Pharmaceuticals will post -3.66 EPS for the current year.

Institutional Trading of Syndax Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Sei Investments Co. boosted its stake in shares of Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock valued at $963,000 after purchasing an additional 991 shares during the period. California State Teachers Retirement System lifted its stake in Syndax Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock worth $1,822,000 after acquiring an additional 1,150 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Syndax Pharmaceuticals in the second quarter worth about $27,000. Ameritas Investment Partners Inc. lifted its stake in Syndax Pharmaceuticals by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after acquiring an additional 1,312 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its stake in Syndax Pharmaceuticals by 28.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock worth $171,000 after acquiring an additional 1,587 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).